COVID-19 enters the body through the airways, but mounting evidence shows it acts largely through the blood vessels. Many researchers now describe it as a vascular disease that masquerades as a respiratory one. The virus doesn’t just damage the lungs. It targets the cells lining blood vessels throughout the body, which explains why it can injure the heart, kidneys, brain, and other organs that seem unrelated to a respiratory infection.
How the Virus Attacks Blood Vessels
SARS-CoV-2 latches onto a protein called ACE2 to enter human cells. ACE2 is found in the lungs, heart, kidneys, intestines, and critically, on endothelial cells, the thin layer of cells that lines every blood vessel in your body. Once the virus infects these endothelial cells, it triggers widespread inflammation of the vessel walls, a condition called endotheliitis. Researchers examining tissue samples from COVID patients found viral particles sitting directly inside endothelial cells across multiple organs.
The damage cascades from there. Infected endothelial cells begin to die off, and the immune system floods the area with inflammatory cells. This shifts the blood vessels into a dysfunctional state: they constrict more than they should, surrounding tissues swell, and the blood itself becomes more prone to clotting. That triple threat of constriction, inflammation, and clotting is what drives organ damage far beyond the lungs.
Why It Looks Like a Respiratory Disease
The confusion is understandable. COVID-19 starts with a cough, sore throat, or shortness of breath. The lungs are the first and most obvious target. But the vasculature is the common thread connecting every major complication. Tiny blood clots form in the lung’s smallest vessels, which is partly why some patients develop such severe breathing problems even when their airways aren’t heavily congested. The same clotting and vessel damage happening in the lungs also happens in the heart, kidneys, and brain.
The BMJ put it plainly: the virus enters through the airways but exerts its systemic effects through the vasculature, making the blood vessels the common denominator across affected organs.
Blood Clots and Cardiovascular Complications
One of the clearest signs of COVID’s vascular nature is how frequently it causes blood clots. Among hospitalized patients, pulmonary embolisms (clots that travel to the lungs) occur in roughly 12% of cases. In intensive care, that rate climbs to an estimated 14 to 23%. These numbers are far higher than what you’d expect from a typical respiratory virus.
The cardiovascular toll extends well beyond clotting. Between 6% and 25% of hospitalized COVID patients experience acute cardiac injury. A 2020 study found that 14.1% of hospitalized patients had some type of cardiovascular complication. For people with severe infections requiring hospitalization, the risk of heart attack and stroke was four times that of people without COVID, an increase in risk equivalent to having pre-existing coronary artery disease.
Doctors noticed early in the pandemic that a blood marker called D-dimer, which rises when the body is actively breaking down clots, was unusually elevated in COVID patients. A French study of nearly 2,900 hospitalized patients found that those admitted with high D-dimer levels had roughly three times the odds of dying in the hospital, independent of whether they were formally diagnosed with a blood clot. The clotting process was happening at a microscopic level throughout the vascular system, even when large clots weren’t detected.
Damage Across Multiple Organs
Once the endothelial lining is compromised, tiny clots can form in the smallest blood vessels of virtually any organ. This microvascular thrombosis is a key driver of multi-organ failure in severe COVID cases.
- Heart: The virus can directly injure heart muscle, and widespread microvascular clotting restricts blood flow to cardiac tissue. This leads to the acute cardiac injury seen in a significant percentage of hospitalized patients, even those with no prior heart disease.
- Kidneys: Acute kidney injury is common in severe COVID. The virus appears to have a tropism for kidney cells, and the combination of direct viral damage and impaired blood flow through tiny renal vessels can push kidneys toward failure.
- Brain: Ischemic strokes have been documented in COVID patients, including younger adults with no traditional stroke risk factors. The general pattern of endothelial damage and microvascular clotting extends to cerebral blood vessels.
This multi-organ pattern is what separates COVID from a straightforward lung infection. Influenza can certainly cause complications outside the lungs, but the scale and consistency of vascular involvement in COVID is distinctive.
Vascular Damage Persists After Recovery
The vascular dimension of COVID doesn’t necessarily resolve when the acute infection clears. Cardiovascular risk remains elevated for at least 12 months after infection. Markers of inflammation and endothelial activation stay elevated for at least six months, suggesting the blood vessel lining continues to malfunction long after the virus itself is gone.
A large study of nearly 154,000 U.S. veterans found that between 30 days and one year after infection, they had higher rates of cerebrovascular disorders, irregular heart rhythms, heart disease, heart failure, inflammation of the heart lining, and blood clots compared to more than 5 million controls. This wasn’t limited to people who had severe infections.
Research published in 2024 in JACC: Advances confirmed that both large and small blood vessel dysfunction, along with increased arterial stiffness, persists for weeks to months after acute infection. This was true even in patients who hadn’t been formally diagnosed with Long COVID. Disruptions in gut bacteria lasting at least six months after infection were also linked to greater residual inflammation and impaired blood vessel function, hinting at a gut-vascular connection in ongoing symptoms.
How This Changed Treatment
Recognizing COVID’s vascular nature fundamentally shifted how hospitals manage severe cases. Blood-thinning medications became a standard part of care, not just for patients with confirmed clots but as a preventive measure.
Current guidelines from the American Society of Hematology recommend that hospitalized COVID patients who aren’t critically ill receive therapeutic-intensity blood thinners as prevention, even without confirmed clots. For critically ill patients, the recommendation is more conservative: lower, prophylactic doses, because these patients also face significant bleeding risks. The balance tips differently depending on individual clotting and bleeding risk.
After hospital discharge, routine blood thinner use is generally not recommended for most patients, though it may be considered for those judged to be at particularly high clotting risk. These guidelines reflect how central vascular management has become to COVID treatment, something that would have seemed unusual for a “respiratory virus” in early 2020.
Respiratory Disease, Vascular Disease, or Both
The most accurate answer is that COVID-19 is a systemic disease with a prominent vascular component. It enters through the respiratory tract, and for many people, it stays a mild respiratory illness. But in moderate to severe cases, the vascular system becomes the primary battleground. The hallmark features of serious COVID, including endothelial activation, microthrombosis, and barrier dysfunction, arise from a combination of direct viral injury and the immune system’s inflammatory overreaction, particularly interactions between platelets and immune cells that push the blood into a hypercoagulable state.
Calling COVID purely a respiratory disease understates its reach. Calling it purely a vascular disease overlooks that it begins in and often stays confined to the airways. The framing that has gained the most traction among researchers is that COVID is a respiratory infection with vascular consequences, and those vascular consequences are what make it so dangerous.